Number of partners
President and CEO
Chief Scientific Officer
Founder and Managing Partner, Proteus Venture Partners
Regenerative medicine (RM)-based therapies hold enormous potential to repair, regenerate or replace diseased cells, tissues and organs. But many of these potentially life-changing treatments never reach patients because they are not successfully moved from the lab to the clinic. Fortunately, Canada is a global hotbed for stem cell research, bioengineering and biomaterials. Building on this expertise, stem cell scientists and bioengineers across six RM centres in Ontario supported the creation of a new commercialization centre that would bridge the gap between academia and industry and enable promising technologies to reach the market. By integrating Canada’s strength in stem cell and biomaterials sciences with dynamic business leadership and the formation of an industry consortium of nearly 40 companies, CCRM is becoming a global nexus of RM commercialization.
The Centre for Commercialization of Regenerative Medicine overcomes two major bottlenecks in RM commercialization: a dearth of early stage capital and access to centralized research infrastructure. CCRM provides small- and medium-sized enterprises, large multinationals and emerging biotechnology companies with a single entry point for accessing Canada-wide RM expertise and infrastructure. CCRM’s industry consortium of nearly 40 Canadian and international RM companies can also access a fully resourced, 550 sq metre development facility designed for bioprocess optimization. CCRM is capitalizing on its extensive pipeline of ideas to bundle promising technologies into 10 new companies that are strategic and leverage expertise, funding and excellent science.